BioMarin Pharmaceutical | BMRN - Gross Profit On Sales


BioMarin Pharmaceutical reported $713.01M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Bayer EUR 5.35B 1.02B Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Incyte USD 1.17B 217.51M Mar/2026
Insmed USD 217.69M 106.25M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Moderna USD 226M 583M Dec/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 3.02B Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
United Therapeutics USD 315.5M 286.6M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025